Nucleolin (NCL, C23) is an important nucleocytoplasmic multifunctional protein. Due to its multifaceted profile and high expression in cancer, NCL is considered to be a marker of drug resistance associated with chemotherapy. However, the biochemical mechanisms in which NCL suppresses drug sensitivity in several cancers have yet to be fully elucidated. This study aims to explore the effect of NCL on drug sensitivity and its potential mechanism in CA46 Burkitt's lymphoma (BL) cells. CA46 BL cells were transfected with lentiviruses carrying the NCL gene (CA46-NCL-overexpression, CA46-NCL-OE), or shRNA sequences that target the endogenous NCL gene (CA46-NCL-knockdown, CA46-NCL-KD). Adriamycin (ADM) IC50 levels for CA46-NCL-overexpressed (OE), CA46-NCL-OE control (OEC), CA46-NCL-knockdown (KD), and CA46-NCL-KD control (KDC) cells were 0.68 ± 0.06 μg/ml, 0.68 ± 0.06 μg/ml, 0.68 ± 0.06 μg/ml, and 0.30 ± 0.04 μg/ml, respectively. Apoptosis rates were significantly increased following NCL KD, whereas the opposite effect was noted in OE cells. A significant reduction of B-cell lymphoma 2 (Bcl-2) mRNA and protein levels in KD cells was observed, while OE cells displayed the opposite effect. The stability of Bcl-2 mRNA was influenced by NCL levels, the half-life of which was extended after NCL-OE, whereas it was reduced in KD cells. Finally, results of RNA-immunoprecipitation assays indicated that NCL could bind to Bcl-2 mRNA in CA46 cells. Taken together, these results suggested that NCL could mediate Bcl-2 expression and stability, and thus enhance ADM resistance in CA46 BL cells.
| INTRODUCTION
Burkitt's lymphoma (BL) is a high-grade, rapidly growing and aggressive B-cell non-Hodgkin's lymphoma. There are three forms of BL: those endemic to Africa, sporadic forms, and those associated with immunodeficiency states (Said, Lones, & Yea, 2014) . Currently, chemotherapy remains the main approach for BL treatment.
However, chemotherapeutic drug resistance during treatment leads to treatment failure and inferior prognosis, and has therefore become a significant challenge (Richter-Larrea et al., 2010) .
Nucleolin (NCL, C23) is an important nucleocytoplasmic multifunctional protein that is abundantly expressed in the nucleolus, nucleoplasm, cytoplasm, and cell membrane (Srivastava & Pollard, 1999) . The three main structural domains of this protein enable its interaction with different proteins and RNA sequences. NCL has been found to be involved in a variety of cellular functions, such as cell proliferation, angiogenesis, apoptosis regulation, stress response, and microRNA processing (Jia, Yao, Zhao, Guan, & Gao, 2017) . Moreover, NCL is responsible for the stability of various protein molecules involved in the apoptosis process (C. Y. Chen et al., 2000; Sengupta, Bandyopadhyay, Fernandes, & Spicer, 2004) . The increased expression of plasma membrane NCL has been observed in a series of tumor cells, which has also been found to contribute to oncogenesis (El Khoury et al., 2010; Hoja-Lukowicz et al., 2009; Lv et al., 2015; Reyes-Reyes & Akiyama, 2008) . Moreover, NCL expression is significantly raised in HL-
60/ADR (HL-60 adriamycin [ADM] resistant cells) compared to parental
HL-60 leukemia cells (Hu et al., 2011) . Due to its multifaceted profile and high expression in tumor cells-particularly drug-resistant tumor cells-NCL may act as an oncogene and drug-resistant pusher. However, the internal biochemical mechanisms that elevate nucleolin and are involved in cellular drug resistance have yet to be elucidated.
The B-cell lymphoma 2 (Bcl-2) gene is highly expressed in more than half of cancer cell types and encodes a 29-kD protein that functions as an inhibitor of cell apoptosis (Amundson et al., 2000) . It has been demonstrated that Bcl-2 was overexpressed, leading to apoptosis inhibition during the development of a variety of tumors (Buggins & Pepper, 2010; Khan & Kahl, 2018; Kulsoom et al., 2018) . Studies have clarified that Bcl-2 protein overexpression results in an apoptosis inhibition effect, which subsequently leads to chemotherapy resistance in hematological tumors and other solid tumors (Pan et al., 2015; RuefliBrasse & Reed, 2017; Weller, Malipiero, Aguzzi, Reed, & Fontana, 1995) .
High NCL and Bcl-2 expression in tumor cells, along with their involvement in cell apoptosis, suggests that they play a relevant role in tumor cell drug resistance. Recent studies have found NCL to be a Bcl-2 mRNA stabilizing protein in HL-60 leukemia cells (Otake, Sengupta, Bandyopadhyay, Spicer, & Fernandes, 2005) . This protein binds specifically to the ARE-1 instability element in the 3′-untranslated region (3′-UTR) of the Bcl-2 mRNA to protect it from ribonuclease degradation. However, the effects of the differential expression of NCL in BL cells with regard to chemotherapeutic drug resistance are unclear.
We hypothesize that the regulation of Bcl-2 mRNA stability by NCL may contribute to drug resistance in BL. To address this hypothesis, we established NCL stable expressing cell models using lentivirus-mediated NCL overexpression (OE) or NCL knockdown (KD) in CA46 BL cells, and thus determined that Bcl-2 (on a molecular level) likely involved in the contribution of NCL with respect to drug resistance.
| MATERIAL AND METHODS

| Cell culture
The human BL cell line CA46, with STR authentication and no mycoplasma contamination, was maintained at the Fujian Institute of Hematology (Fuzhou, China). CA46 cells were grown at 37°C under a 5% CO 2 in a humidified atmosphere (HealthForce, Shanghai, China) in RPMI 1640 medium (Hyclone, UT) and supplemented with 10% heat-inactivated fetal bovine serum (Hyclone).
| Lentivirus-mediated NCL KD and OE
Human NCL shRNA and the control scramble shRNA oligonucleotides, respectively, were cloned into pGCL-tet-puro-EGFP vectors The primers used to amplify the NCL gene were as follows:
NCL OE:
sense: 5′-GAGGATCCCCGGGTACCGGTCGCCACCATGGTGAA GCTCGCGAAGGCAG-3, antisense: 5′-TCCTTGTAGTCCATACCTTCAAACTTCGTCTTCTT TCC-3.
| MTS assay
ADM was purchased from Sigma-Aldrich (St. Louis, MO), and then diluted with a stock concentration of 2 mg/ml. The ADM sensitivity 2.4 | Analysis of apoptosis using flow cytometry and 4′,6-diamidino-2-phenylindole (DAPI) staining were detected and quantified using BD FACSCanto™Ⅱanalysis (BD Biosciences). Flow cytometry data were analyzed using FlowJo7.6.1 (Tomy Digital Biology, Tokyo, Japan).
For DAPI staining assay, the CA46 cells and posttransduction cells were suspended in phosphate-buffered saline (PBS) and stained with DAPI, according to the manufacturer's protocol (Beyotime, Hangzhou, China). The apoptotic cells were imaged using a fluorescence microscope.
| Quantitative real-time PCR (qPCR)
Total RNA was extracted using a TRIzol reagent (Life Tech Invitrogen, Carlsbad, CA) and subjected to reverse-transcription with a GoScript™
Reverse-Transcription System kit, according to the manufacturer's protocol (Promega). cDNA was amplified using a SYBR Green PCR master mix with a GoTaq ® qPCR Master Mix kit (Promega). The PCR was performed with a PE ABI-7500 Real-Time PCR system (Applied Biosystems, Carlsbad, CA). The results were analyzed using the ΔCT and −2 ΔΔCT quantification method in the ABI-7500 software (Applied Biosystems), as previously described (Lin et al., 2013) . The gene primers sequence were as follows: Bcl-2: forward: 5′-GAACTGGGGGAGGA TTGTGG-3′, reverse: 5′-CCGTACAGTTCCACAAAGGC-3′; NCL: forward: 5′-CTTGCTGTTGTGGATGTC-3′, reverse: 5′-CATGGCGTCTTC AAACAC-3′; GAPDH: forward: 5′-CAGCTGGCCATCGAGATCA-3′, reverse: 5′-TCCAGTCTCTGAGCCTCATGC-3′.
| Determination of Bcl-2 mRNA stability with actinomycin D (Act D)
The CA46 cells were seeded at a density of 2 × 10 5 cells/ml, and 2 µg/ ml Act D (Sigma-Aldrich) was added. The final ethanol concentration did not exceed 0.5%. The cells were cultured at 37°C in 5% CO 2 , and subsequently harvested starting at 0 hrs, and then for every 60 min for the following 8 hrs. At this concentration, Act D did not induce DNA fragmentation during the given time period. Total RNA was isolated and the level of Bcl-2 mRNA was detected using qPCR.
| Western blot analysis
Western blot was performed, as previously described (Hu et al., 2011) . The primary antibodies used for western blot analysis were as follows: NCL, Bcl-2, β-actin (Santa Cruz, CA), caspase3, and cleaved caspase3 (Cell Signaling Technology, Danvers, MA). Anti-mouse and anti-rabbit secondary antibodies were used in accordance with the manufacturer's recommendation (Santa Cruz). Proteins were detected using a chemiluminescent substrate (ECL; Beyotime).
| Coimmunoprecipitation of NCL protein and Bcl-2 mRNA complexes
The immunoprecipitation of NCL protein and Bcl-2 mRNA complexes was undertaken according to the instructions provided by the manufacturer (EZ-Magna RIP Kit, Millipore, Billerica, MA). Briefly, CA46 cells were lysed in RIPA lysis buffer. A total of 5 µg of anti-NCL antibody (Santa Cruz) was cross-linked with protein A/G magnetic beads, for which mouse IgG was used as a control antibody. Then, the cell lysates were incubated with the cross-linked magnetic beads overnight at 4°C in a RNA-immunoprecipitation (RIP) buffer. The magnetic beads were eventually washed off from any unbound material. Proteinase K buffer was used to digest the proteins in magnetic beads. The RNA was extracted and purified with a phenol:chloroform:isoamyl alcohol mixture. The cDNA was synthesized using random hexamer primers and reverse transcriptase, as described above. RT-PCR was conducted under the following conditions: initial denaturation for 10 min at 95°C, followed by 40 cycles of denaturation at 95°C for 15 s and amplification at 60°C for 60 s. The PCR products were separated on 1.5% agarose gels and stained with GoldView, and the results were quantified by determining the band intensity using Bio-Rad ChemiDoc™ Touch (Bio-Rad Laboratories, Hercules, CA).
| Statistical analysis
The results are presented as the mean ± SD of the three independent experiments. The differences among the groups were analyzed using a one-way analysis of variance with Tukey's test for post hoc analysis.
The significance was evaluated using GraphPad Prism 6.0 software (Version6.0; GraphPad, San Diego, CA). A value of 0.05 or lower was considered to represent a statistically significant difference between the groups.
| Statement of ethics
Neither human studies nor animal studies were applied in this study.
3 | RESULTS
| ADM resistance was affected by NCL in CA46 cells
To investigate the effect of NCL on drug resistance in BL cells, a CA46-NCL-OE and KD cell model were established by lentivirus transfection, respectively, and subsequently validated at both the mRNA and protein level (Figure 1a,b) . The data indicated that the CA46, OEC, and KDC groups exhibited similar NCL levels, whereas in KD cells, the mRNA level and protein expression of full-length NCL Figure 1c) . Thus, the data suggested that NCL played a role in promoting cellular drug resistance.
| NCL played a role in apoptosis induction in CA46 cells
Cell apoptosis was detected in CA46-NCL-OE and CA46-NCL-KD cells, and their corresponding control groups. Using the annexin V assay and the DNA intercalator 7-AAD staining assay, KD cells exhibited more intense apoptosis than their control cells (p < .05; Figure 2a ). Conversely, apoptosis rates decreased after NCL OE (p < .01; Figure 2b ). Cell apoptosis was also confirmed by DAPI staining assay and caspase3 protein test. Nucleus DAPI staining was increased in KD cells, but decreased in OE cells. Caspase3 were activated in KD cells (Figure 2c,d) . Thus, the results suggested that NCL was involved in apoptosis in CA46 cells.
| NCL affected expression levels of Bcl-2 mRNA and protein
OE of Bcl-2 can confer cell resistance to a variety of anticancer drugs through the inhibition of apoptosis (Pan et al., 2015) . To investigate whether BCL-2 is involved in the apoptosis inhibition effect of NCL OE on CA46 cells, the mRNA and protein levels of Bcl-2 were detected using qPCR and western blot assays, respectively. As expected, Bcl-2 protein levels (in accordance with mRNA levels) increased after NCL OE and were reduced following NCL KD (p < .01; 
| Effect of NCL in Bcl-2 mRNA stability
To uncover the biological mechanism underlying the expression regulation effect of NCL on Bcl-2, an Act D test was used to determine whether NCL modulated Bcl-2 expression by mRNA stability regulation. The RNA polymerase inhibitor Act D binds DNA in a guanine-dependent manner and interferes with RNA polymerase and DNA topoisomerase enzymes. Whereas, at low concentrations (up to 5 µg/ml), it is a strong and specific inhibitor of ribosomal gene transcription (Pan et al., 2015) . A significant decrease of Bcl-2 mRNA in KD cells was noted compared to KDC cells at 3, 4, 5, 6, 7 and 8 hrs,
following incubation with Act D (Figure 4a ). At all-time points
(1-8 hrs), groups KDC, OEC, and CA46 exhibited a similar decline tendency in Bcl-2 mRNA levels, which were lower and higher than the corresponding levels in the OE and KD cells, respectively ( Figure   4a ). The half-life of Bcl-2 mRNA was extended from 5.22 ± 0.21 hrs in OEC cells to 6.95 ± 0.13 hrs in OE cells, whereas it declined from 4.86 ± 0.15 hrs in KDC cells to 3.23 ± 0.18 hrs in KD cells (Figure 4a ).
The results indicated that Bcl-2 mRNA stability increased with NCL OE, and decreased with NCL KD. Thus, NCL was confirmed to positively impact Bcl-2 mRNA stability. (Dlugosz & Janecka, 2016; Morabito et al., 1997; Tsuchiya et al., 2015) . In this study, we found that NCL OE can promote drug resistance in BL, a result which may be related to the stabilization of Bcl-2 mRNA and decreased induction of apoptosis.
NCL is closely related to the proliferation and survival of cancer cells. Several studies have suggested that this protein exhibits a high expression in malignant cells, most notably in tumor cells (Pichiorri et al., 2013; Shen et al., 2014; Zhao et al., 2013) . Clinically, overexpressed NCL in relapse/refractory acute leukemia patient's cells with poor prognosis was found in our group's study (Hu et al. , ). It has been reported that high NCL expression level in AML blasts is associated with poor overall survival rates (Marcel et al., 2017) . Biologically, NCL is known to act in proliferation promotion and drug resistance evolution in acute leukemia cells (Westmark & Malter, 2001) . It has been suggested that chemotherapeutic druginduced apoptosis in HL-60 cells is preceded by the Bcl-2 mRNA destabilization and the downregulation of Bcl-2 mRNA and protein levels (Bandyopadhyay, Sengupta, Fernandes, & Spicer, 2003; Riordan, Foroni, Hoffbrand, Mehta, & Wickremasinghe, 1998) . In addition, Westmark and Malter have suggested that NCL downregulation is an essential step for the antitumor effects of chemotherapeutic drugs (Westmark & Malter, 2001 ). Our previous studies had noted that NCL is overexpressed in the ADM resistance Cheng et al., 2016; Soundararajan et al., 2008) . In CLL cells, loss of NCL activates Fas-mediated apoptosis. In B-cell lymphoma, NCL KD sensitized cells to FasL-induced apoptosis and induced phosphorylation of H2AX and B-cell lymphoma survival (Jain et al., 2017; Kaufman et al., 2015; Wise et al., 2013) . One study notably investigated perinucleolar localization and the binding of NCL to the CCND1 allele, which encoded the transcription of the cyclin D1 protein in mantle cell lymphoma (Allinne et al., 2014) . Nevertheless, with regard to BL and NCL, current studies are limited. NCL was first identified as an apoptosis-associated protein in human BL cells in 1998 (Brockstedt et al., 1998) and thus regulated the expression of the Bcl-2 gene. This finding was in accordance with previous studies that have examined in different cell types (Kito et al., 2003; Otake et al., 2005; Sengupta et al., 2004) .
Using the Act D test, our study confirmed that NCL modulated Bcl-2 expression via mRNA stability regulation. Moreover, we demonstrated a physical binding of NCL protein and Bcl-2 mRNA in BL cells.
Previous studies have found that the NCL protein specifically bonds to the ARE-1 instability element in the 3′-UTR of the Bcl-2 mRNA to protect it from ribonuclease degradation (Otake et al., 2005) .
Furthermore, immunoprecipitation assays have indicated that the binding of NCL and Bcl-2 mRNA transcripts enhances Bcl-2 stability, most likely by protecting the mRNA from exosome recruitment and subsequent decay (Ishimaru et al., 2010) . While previous studies have determined the binding site of NCL and Bcl-2 mRNA, our study clarified the modulation of NCL on the stability of BCL mRNA, the clue of which NCL modulates the stability of Bcl-2 mRNA by directly binding to the mRNA transcript. The above results revealed the location of the binding site and the effect of NCL on Bcl-2.
In conclusion, our study has demonstrated that high NCL expression promotes drug resistance in BL, which may be related to the stabilization of Bcl-2 mRNA and the decreased induction of apoptosis. Importantly, NCL can bind directly to Bcl-2 mRNA, thus modulating its stability. The data provide insight into the regulation of cancer aggressiveness and drug sensitivity via the inhibition of NCL expression in tumors. Thus, NCL could be used as a potential therapeutic target in BL. 
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